Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

ConclusionsRA patients treated with IV golimumab or infliximab achieved comparable improvements across social, mental, and physical well-being PROMIS measures. Additionally, PROMIS detected meaningful clinical changes in patient-reported outcomes in both treatment groups.ClinicalTrials.gov registration numberNCT02728934.

http://link.springer.com/10.1007/s40744-023-00533-5

Source: Rheumatology and Therapy - February 23, 2023 Category: Rheumatology Source Type: research